

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Claus Schmidt Møller

Application No.: To Be Assigned

Group Art Unit: TBA

Filed: September 22, 2003

Examiner: TBA

For: Injection Device

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no material references other than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. **Copies of all references were either submitted to, or cited by, the Patent Office in parent application USSN 09/882,536 filed on June 14, 2001.** The references are as follows:

1. US Patent No. 4,470,317
2. US Patent No. 4,585,439
3. US Patent No. 6,074,372
4. US Patent No. 5,743,889
5. US Patent No. 4,883,472


6. US Patent No. 6,003, 736
7. US Patent No. 5,112,317
8. FR 2,767,479
9. WO 99/38554
10. DE-OS 36 09 555
11. FR 2,583,291
12. WO 98/57688
13. WO 96/26754
14. US Patent No. 6,221,053
15. US Patent No. 5,626,566
16. US Patent No. 4,498,904
17. US Patent No. 6,004,297
18. US Patent No. 5,304,152

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed **within** three months of the filing date of a national application or date of entry into the national stage of an international application or **before** the mailing date of a first Office action on the merits, or **before** the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due. However, please charge any fees should they be required, to Novo Nordisk Pharmaceuticals, Inc. Deposit Account No. 14-1447.

Respectfully submitted,

Date: September 22, 2003



Marc A. Began, Reg. No. 48,829  
Novo Nordisk Pharmaceuticals, Inc.  
100 College Road West  
Princeton, NJ 08540  
(609) 987-5800

23650

PATENT TRADEMARK OFFICE

FORM PTO-1449  
(Rev. 2-32)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

Atty. Docket No. 6196.210-US

Serial No. To Be Assigned

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

Applicant Claus Schmidt Møller

(Use several sheets if necessary)

Filing Date September 22, 2003

Group TBA

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	4,470,317	9/84	Sabloewski et al.			
	4,585,439	4/86	Michel			
	6,074,372	6/00	Hansen			
	5,743,889	4/98	Sams			
	4,883,472	11/89	Michel			
	6,003,736	12/99	Ljunggren			
	5,112,317	5/92	Michel			
	6,221,053	4/01	Walters et al.			
	5,626,566	5/97	Petersen et al.			
	4,498,904	2/85	Turner et al.			
	6,004,297	12/99	Steenfeldt-Jensen et al.			
	5,304,152	4/94	Sams Bernard			

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	FR 2,767,479	2/99	France				
	WO 99/38554	8/99	PCT				
	DE-OS 3609555	9/87	Germany				
	FR 2,583,291	12/86	France				
	WO 98/57688	12/98	PCT				
	WO 6/26754	9/96	PCT				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)


EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.